BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NovaBridge Biosciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies NovaBridge Biosciences's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06984588-2193@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20280805
DTEND;VALUE=DATE:20280806
SUMMARY:Uliledlimab: Phase 2/3 readout est. (NCT06984588)
DESCRIPTION:Uliledlimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Compare Uliledlimab Combined With Toripalimab\, Toripalimab Mono
 therapy\, and Pembrolizumab Monotherapy in Patients With Previously Untrea
 ted Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected 
 Non-Small Cell Lung Cancer\nEstimated primary completion: 5 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/uliledlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06984588
URL:https://assetmemo.bio/drug/uliledlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-10902@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:givastomig: Phase 2 readout est. (NCT07432295)
DESCRIPTION:givastomig\, phase 2\, Gastric Cancer.\nStudy: Givastomig Combi
 ned With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metas
 tatic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/givastomig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/givastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
